

INDEX		
SR. NO.	TITLE	PAGE NO.
1	INTRODUCTION	01
2	LITERATURE REVIEW	07
2.1.	Introduction	08
2.2.	History of Diabetes Mellitus	08
2.3.	Discovery of Insulin	10
2.4.	Mechanism if Insulin action	12
2.5.	Classification of diabetes mellitus	13
2.5.1.	Modern Classification System for Diabetes Mellitus	13
2.5.2	American Diabetes Association Classification System	16
2.6.	Type 1 Diabetes Mellitus	17
2.7.	Type 2 Diabetes Mellitus	20
2.8.	Other Specific Types of Diabetes mellitus	21
2.9.	Gestational Diabetes Mellitus	25
2.10.	Sign and symptoms of diabetes mellitus.	25
2.11.	Prevalence of diabetes mellitus	27
2.11.1.	Prevalence of diabetes in India and Asian countries.	27
2.11.2	Global Prevalence of Diabetes	28
2.12.	Diagnostic criteria for Diabetes Mellitus	29
2.13.	Glycated Haemoglobin (HbA1c) For The Diagnosis Of Diabetes	32
2.14.	Diabetic Complications	37
2.14.1	Acute complication	37
2.14.1.1	Diabetic Ketoacidosis	37
2.14.1.1.1	Diagnosis	38
2.14.1.2.	Lactic Acidosis	39
2.14.1.3.	Hypoglycaemia	39
2.14..1.3.1.	Symptoms of Hypoglycemia	39

2.14.2	Chronic Complication	40
2.14.2.1	Classification of chronic complications	41
2.14.2.2.	Microvascular Complication.	41
2.14.2.2.1.	Retinopathy	41
2.14.2.2.2	Nephropathy	42
2.14.2.2.3	Neuropathy	43
2.14.2.3	Macrovascular	43
2.14.2.3.1.	Coronary Heart diseases	44
2.14.2.3.2.	Peripheral Vascular Disease	44
2.14.2.3.3.	Cerebrovascular Disease	45
2.15.	Treatment of diabetes mellitus	45
2.16.	Therapeutic options	46
2.17.	Oral Antidiabetic Agents	48
2.18.	Classification of antidiabetic agents	48
2.19.	Insulin Secretagogues	49
2.19.1.	Sulphonylureas	49
2.19.1.1.	Mechanism of action of Sulphonylureas.	49
2.19.1.1.1.	Pancreatic mechanism	49
2.19.1.1.2.	Extra Pancreatic Mechanisms	50
2.19.1.2.	Generations of sulphonylureas.	50
2.19.1.3.	Mechanism of action of Sulphonylureas.	51
2.19.1.4.	Pharmacokinetics of first and second generation Sulphonylureas.	53
2.19.1.5.	Indications and Contraindications.	53
2.19.1.6.	Efficacy	54
2.19.1.7.	Adverse Events	56
2.19.2.	Meglitinide analogues	57
2.19.2.1.	Mode of action of Action Meglitinide.	57
2.19.2.2.	Pharmacokinetics	58

2.19.2.3.	Indications and Contraindications	58
2.19.2.4.	Efficacy	59
2.19.2.5.	Adverse Events	59
2.19.3.	Insulin Sensitizer	60
2.19.3.1.	Bigunides.	60
2.19.3.1.1.	Metformin	60
2.19.3.1.2.	Mode of action of Action Bigunides	61
2.19.3.1.3.	Pharmacokinetics	63
2.19.3.1.4.	Indications and Contraindications	64
2.19.3.1.5.	Efficacy	65
2.19.3.1.6.	Adverse Effects	67
2.19.4.	Thiazolidinediones	68
2.19.4.1.	Mode of action of Action Thiazolidinediones	69
2.19.4.2.	Pharmacokinetics	70
2.19.4.3.	Indications and Contraindications	71
2.19.4.4.	Efficacy	73
2.19.4.5.	Adverse Effects	75
2.19.5.	Dipeptidyl peptidase-4 (DPP-4) inhibitors	75
2.19.5.1.	Mode of action	76
2.19.5.2.	Pharmacokinetics	78
2.19.5.3.	Indications and Contraindications	81
2.19.5.4.	Efficacy.	81
2.19.5.5.	Adverse Effects	83
2.19.6.	Alpha Glucosidase Inhibitors	85
2.19.6.1.	Mode of Action of alpha glucosidase Inhibitor	85
2.19.6.2.	Indications and Contraindications	87
2.19.6.3.	Efficacy	88
2.19.6.4.	Pharmacokinetics	89
2.19.6.5.	Adverse Effects	93

2.19.6.6.	Clinical studies of acarbose	94
2.19.6.7.	Clinical studies of Miglitol	94
2.19.6.8.	Clinical studies of Voglibose	95
2.20.	Alpha glucosidae inhibitor from plant source	96
2.21.	<i>Salacia Oblonga</i>	96
2.22.	<i>Salacia reticulata</i>	99
03	AIM AND OBJECTIVES	102
04	MATERIALS AND METHODS	104
4.1	Study Design	105
4.2	Duration of Study	105
4.3	Methodlogy	105
4.3.1.	Study Site	105
4.3.2.	Study Design	105
4.3.3.	Study Period	105
4.3.4.	Source of Data	105
4.3.5.	Study Criteria	106
4.3.5.1.	Inclusion Criteria	106
4.3.5.2.	Exclusion Criteria	106
4.3.6.	Study Procedure	107
4.3.7.	Efficacy measures	108
4.3.7.1.	Collection of blood samples	108
4.3.7.2.	Sample Analysis	108
4.3.8.	Blood Glucose estimation	109
4.3.8.1.	Methodology	109
4.3.8.1.1.	Trinder's Method	109
4.3.9.	Calculation	110
4.3.9.1.	Estimation of HbA1C	111
4.3.9.1.1.	Test Principle	112
4.3.9.1.2.	Kit Contents	111

4.3.9.1.3.	Stability and Storage	111
4.3.10.	Sample material	112
4.3.10.1.	Test Procedure	112
4.3.10.2.	Important procedural notes	112
4.3.11.	Sample material	112
4.4.	Statistical Analysis	112
4.5.	Informed Consent	113
4.6.	Ethical Committee Approval	113
4.7.	Dropouts	113
4.8.	Adverse drug reaction	113
4.9.	Flow Chart	114
05	OBSERVATIONS AND RESULTS	115
06	DISCUSSION	139
07	SUMMARY AND CONCLUSION	157
08	REFERENCES	159
09	ANNEXURE	190